D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá

ilustraciones, gráficas, tablas

Autores:: Domínguez Gómez, Carolina

Tipo de recurso:

Fecha de publicación:: 2022

Institución:: Universidad Nacional de Colombia

Repositorio:: Universidad Nacional de Colombia

Idioma:: spa

id	UNACIONAL2_da24745029251d7f0e99eba04afdf5cd
oai_identifier_str	oai:repositorio.unal.edu.co:unal/80937
network_acronym_str	UNACIONAL2
network_name_str	Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá
dc.title.translated.eng.fl_str_mv	D-index as a risk factor for invasive fungal infection in patients with acute lymphoblastic leukemia from a reference hematology center in Bogotá
title	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá
spellingShingle	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá 610 - Medicina y salud::616 - Enfermedades Mycoses Precursor Cell Lymphoblastic Leukemia-Lymphoma Febrile Neutropenia Micosis Leucemia-Linfoma Linfoblástico de Células Precursoras Neutropenia Febril D-index Infección fúngica invasora Factores de riesgo Neutropenia Leucemia linfoblástica aguda D-index Invasive fungal infection Risk factors Neutropenia Acute lymphoblastic leukemia
title_short	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá
title_full	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá
title_fullStr	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá
title_full_unstemmed	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá
title_sort	D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá
dc.creator.fl_str_mv	Domínguez Gómez, Carolina
dc.contributor.advisor.spa.fl_str_mv	Cuervo Maldonado, Sonia Isabel
dc.contributor.author.spa.fl_str_mv	Domínguez Gómez, Carolina
dc.contributor.researchgroup.spa.fl_str_mv	Greicah Grupo en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas
dc.subject.ddc.spa.fl_str_mv	610 - Medicina y salud::616 - Enfermedades
topic	610 - Medicina y salud::616 - Enfermedades Mycoses Precursor Cell Lymphoblastic Leukemia-Lymphoma Febrile Neutropenia Micosis Leucemia-Linfoma Linfoblástico de Células Precursoras Neutropenia Febril D-index Infección fúngica invasora Factores de riesgo Neutropenia Leucemia linfoblástica aguda D-index Invasive fungal infection Risk factors Neutropenia Acute lymphoblastic leukemia
dc.subject.decs.eng.fl_str_mv	Mycoses Precursor Cell Lymphoblastic Leukemia-Lymphoma Febrile Neutropenia
dc.subject.decs.spa.fl_str_mv	Micosis Leucemia-Linfoma Linfoblástico de Células Precursoras Neutropenia Febril
dc.subject.proposal.spa.fl_str_mv	D-index Infección fúngica invasora Factores de riesgo Neutropenia Leucemia linfoblástica aguda
dc.subject.proposal.eng.fl_str_mv	D-index Invasive fungal infection Risk factors Neutropenia Acute lymphoblastic leukemia
description	ilustraciones, gráficas, tablas
publishDate	2022
dc.date.accessioned.none.fl_str_mv	2022-02-10T20:04:20Z
dc.date.available.none.fl_str_mv	2022-02-10T20:04:20Z
dc.date.issued.none.fl_str_mv	2022-01-19
dc.type.spa.fl_str_mv	Trabajo de grado - Especialidad Médica
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/masterThesis
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/acceptedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/TM
status_str	acceptedVersion
dc.identifier.uri.none.fl_str_mv	https://repositorio.unal.edu.co/handle/unal/80937
dc.identifier.instname.spa.fl_str_mv	Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv	Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv	https://repositorio.unal.edu.co/
url	https://repositorio.unal.edu.co/handle/unal/80937 https://repositorio.unal.edu.co/
identifier_str_mv	Universidad Nacional de Colombia Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.indexed.spa.fl_str_mv	Bireme
dc.relation.references.spa.fl_str_mv	Shariati A, Moradabadi A, Chegini Z, Khoshbayan A, Didehdar M. An overview of the management of the most important invasive fungal infections in patients with blood malignancies. Vol. 13, Infection and Drug Resistance. Dove Medical Press Ltd.; 2020. p. 2329–54. Antoniadou A, Giamarellou H. Fever of Unknown Origin in Febrile Leukopenia. Vol. 21, Infectious Disease Clinics of North America. 2007. p. 1055–90. Hsu LY, Lee DG, Yeh SP, Bhurani D, Khanh BQ, Low CY, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: A prospective observational study. Clinical Microbiology and Infection. 2015 Jun 1;21(6):594.e7-594.e11. Fernández-Cruz A, Lewis RE, Kontoyiannis DP. How long do we need to treat an invasive mold disease in hematology patients? factors influencing duration of therapy and future questions. Clinical Infectious Diseases. 2020 Aug 1;71(3):685–92. Peter Donnelly J, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clinical Infectious Diseases. 2020 Sep 15;71(6):1367–76. Stohs E, Zimmer A. An Approach to Suspected Invasive Fungal Infection in Patients with Hematologic Malignancy and HCT Recipients with Persistent Neutropenic Fever Despite Mold-Active Prophylaxis. Vol. 14, Current Fungal Infection Reports. Springer; 2020. p. 89–98. Lien MY, Chou CH, Lin CC, Bai LY, Chiu CF, Yeh SP, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study. PLoS ONE. 2018 Jun 1;13(6). Nucci M, Anaissie E. How I Treat How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. 2014; 124(26):3858-69. Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Vol. 31, Blood Reviews. Churchill Livingstone; 2017. p. 17–29. Kubo H, Imataki O, Kubo YH, Uemura M, Kadowaki N. c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia. International Journal of Clinical Oncology. 2019 May 15;24(5):590–5. Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. Journal of Clinical Oncology. 2009 Aug 10;27(23):3849–54. Yılmaz G, Coşkun B, Elhan A, Azap A, Akan H. D-index: Febril nötropenik hastalarda ınvazif mantar enfeksiyonlarının tanımlanmasında yeni bir skorlama sistemi. Turkish Journal of Hematology. 2016;33(2):102–6. Instituto Nacional de Cancerología – ESE. Anuario estadístico 2017. Volumen 15. Bajpai VK, Khan I, Shukla S, Kumar P, Rather IA, Park YH, et al. Invasive Fungal Infections and Their Epidemiology: Measures in the Clinical Scenario. Vol. 24, Biotechnology and Bioprocess Engineering. Korean Society for Biotechnology and Bioengineering; 2019. p. 436–44. Ko BS, Chen WT, Kung HC, Wu UI, Tang JL, Yao M, et al. 2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. Vol. 51, Journal of Microbiology, Immunology and Infection. Elsevier Ltd; 2018. p. 287–301. Camplesi Junior M, Silva HM, Arantes AM, Costa CR, Ataides FS, Silva TC, et al. Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital. Revista da Sociedade Brasileira de Medicina Tropical. 2017;50(1):80–5. Lee SY, Yeo CL, Lee WH, Kwa AL, Koh LP, Hsu LY. Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in Singapore. BMC Research Notes. 2011;4. Vusirikala M, Supportive care in hematologic malignancies. Wintrobe’s Clinical Hematology. 2009;1747–90. Cooper B, Dubberke ER, Morris Engemann A, Freifeld AG, Greene JN, Ito JI, et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(7):882-913. Douglas AP, Slavin MA. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field. Expert Rev Anti Infect Ther. 2016;14(12):1165-1177. Nicolato A, Nouér SA, Garnica M, Portugal R, Maiolino A, Nucci M. Invasive fungal diseases in patients with acute lymphoid leukemia. Leukemia and Lymphoma. 2016;57(9):2084–9. Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control Journal of Antimicrobial Chemotherapy. 1998;41:95–105. Bodey GP, Buckley M, Sathe YS, Freireich EJ, Bethesda M. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328-40. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345-51. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005 Mar 15;103(6):1103-13. Abers MS, Ghebremichael MS, Timmons AK, Warren HS, Poznansky MC, Vyas JM. A Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis. Open Forum Infect Dis. 2016;3(1):ofw036. Natarajan SK, Narayan S, Liu Yin JA. Update on the Management of Febrile Neutropenia. European Oncology & Haematology, 2011;7(4):263-269 Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013; 2013 (1): 423–427. Portugal RD, Garnica M, Nucci M. D-index and Prediction of Infection. Biol Blood Marrow Transplant 2010; 16: 1608. Garnica M, Sinhorelo A, Madeira L, Portugal R, Nucci M. Diagnostic-driven antifungal therapy in neutropenic patients using the D-index and serial serum galactomannan testing. Brazilian Journal of Infectious Diseases. 2016;20(4):354–9. Kanda Y, Kimura S-I, Iino M, Fukuda T, Sakaida E, Oyake T, et al. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol. 2020;38(8):815-822. Kimura S ichi, Kanda Y, Iino M, Fukuda T, Sakaida E, Oyake T, et al. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial. International Journal of Infectious Diseases. 2020;100:292–7. Kimura S ichi, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Yoshino N, et al. Impact of neutropenia evaluated in terms of the D-index on invasive fungal disease while on empiric or preemptive antifungal treatment strategy in the early phase after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2020 Dec;22(6):e13409. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models Biometrika. 1986; 73(1):13–22
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv	Atribución-NoComercial 4.0 Internacional
dc.rights.uri.spa.fl_str_mv	http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Atribución-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.extent.spa.fl_str_mv	xiii, 34 páginas
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.coverage.city.spa.fl_str_mv	Bogotá
dc.publisher.spa.fl_str_mv	Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv	Bogotá - Medicina - Especialidad en Medicina Interna
dc.publisher.department.spa.fl_str_mv	Departamento de Medicina Interna
dc.publisher.faculty.spa.fl_str_mv	Facultad de Medicina
dc.publisher.place.spa.fl_str_mv	Bogotá, Colombia
dc.publisher.branch.spa.fl_str_mv	Universidad Nacional de Colombia - Sede Bogotá
institution	Universidad Nacional de Colombia
bitstream.url.fl_str_mv	https://repositorio.unal.edu.co/bitstream/unal/80937/1/1110470021.2022.pdf https://repositorio.unal.edu.co/bitstream/unal/80937/2/license.txt https://repositorio.unal.edu.co/bitstream/unal/80937/3/1110470021.2022.pdf.jpg
bitstream.checksum.fl_str_mv	697a63b4b56f8d96312a0361fa158639 8153f7789df02f0a4c9e079953658ab2 702d70cd1fd5f91827e431d7a1addfeb
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv	repositorio_nal@unal.edu.co
_version_	1814089789330161664
spelling	Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Cuervo Maldonado, Sonia Isabelf1527f7e8c17063488637800403259a4600Domínguez Gómez, Carolinaa4ab419bbecc94315c445e0de6228b96600Greicah Grupo en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas2022-02-10T20:04:20Z2022-02-10T20:04:20Z2022-01-19https://repositorio.unal.edu.co/handle/unal/80937Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, gráficas, tablasLos pacientes con neoplasias hematológicas son huéspedes susceptibles para el desarrollo de infección fúngica invasora. Actualmente, se dispone de estrategias de profilaxis antifúngica, esquemas de tratamiento antimicótico y, se reconoce como uno de los principales factores de riesgo, la neutropenia profunda y prolongada. El D-index acumulado es un parámetro cuantitativo diseñado en 2009, que determina la severidad de la neutropenia, evaluando el déficit acumulativo de neutrófilos <500 células/μL, desde el inicio del episodio hasta la aparición de la primera manifestación clínica de infección. Objetivo general: El presente estudio propone estimar la fuerza de asociación del D-index acumulado, para el desarrollo de infección fúngica invasora, en pacientes con leucemia linfoblástica aguda. Materiales y métodos: Estudio de casos y controles, en mayores de 18 años, con leucemia linfoblástica aguda, admitidos entre 2009 y 2019 en el Instituto Nacional de Cancerología, para quimioterapia de inducción y consolidación. Resultados: Se incluyeron 156 pacientes, quienes aportaron 264 ciclos de quimioterapia, como unidad de análisis. Se construyó un modelo GEE para analizar datos longitudinales correlacionados. En este modelo se incluyeron 3 variables cuantitativas continuas: edad (años), el D-index y la neutropenia profunda (días). Sólo el D-index demostró ser la variable significativa, con un OR= 1,000304 (IC 95% 1.0002 – 1.0004); p > 0,001. Conclusiones: El D-index acumulado se asocia con el desarrollo de IFI en pacientes con leucemia linfoblástica aguda, con aumento del OR conforme aumenta el D-index, siendo mayor cuando el valor de D-index supera el valor de 4.208. (Texto tomado de la fuente).Patients with hematologic malignancies are susceptible hosts for the development of invasive fungal infection. Currently, there are antifungal prophylaxis strategies, antifungal treatment schemes, and profound and prolonged neutropenia is recognized as one of the main risk factors. The cumulative D-index is a calculated parameter designed in 2009, which determines the severity of neutropenia, evaluating the cumulative deficit of neutrophils <500 cells/μL, from the start of the episode until the appearance of the first clinical manifestation of infection. Objective: The present study proposes to estimate the strength of association of the accumulated D-index, for the development of invasive fungal infection, in patients with acute lymphoblastic leukemia. Methods: Case-control study, in patients over 18 years of age, with acute lymphoblastic leukemia, admitted between 2009 and 2019 at the National Cancer Institute, for induction and consolidation chemotherapy. Results: 156 patients were included, who provided 264 cycles of chemotherapy, as the unit of analysis. A GEE model was built to analyze correlated longitudinal data. This model includes 3 continuous quantitative variables: age (years), the D-index and profound neutropenia (days). Only the D-index stood out as the significant variable, with an OR= 1.000304 (95% CI 1.0002 – 1.0004); p > 0.001. Conclusions: The accumulated D-index is associated with the development of IIF in patients with acute lymphoblastic leukemia, with an increase in the OR as the D-index increases, being higher when the value of D-index exceeds the value of 4.208.Incluye anexosEspecialidades MédicasEspecialista en Medicina InternaEstudio de casos y controles, no pareado.Infecciones fúngicas en pacientes con cáncerxiii, 34 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Especialidad en Medicina InternaDepartamento de Medicina InternaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y salud::616 - EnfermedadesMycosesPrecursor Cell Lymphoblastic Leukemia-LymphomaFebrile NeutropeniaMicosisLeucemia-Linfoma Linfoblástico de Células PrecursorasNeutropenia FebrilD-indexInfección fúngica invasoraFactores de riesgoNeutropeniaLeucemia linfoblástica agudaD-indexInvasive fungal infectionRisk factorsNeutropeniaAcute lymphoblastic leukemiaD-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de BogotáD-index as a risk factor for invasive fungal infection in patients with acute lymphoblastic leukemia from a reference hematology center in BogotáTrabajo de grado - Especialidad Médicainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TMBogotáBiremeShariati A, Moradabadi A, Chegini Z, Khoshbayan A, Didehdar M. An overview of the management of the most important invasive fungal infections in patients with blood malignancies. Vol. 13, Infection and Drug Resistance. Dove Medical Press Ltd.; 2020. p. 2329–54.Antoniadou A, Giamarellou H. Fever of Unknown Origin in Febrile Leukopenia. Vol. 21, Infectious Disease Clinics of North America. 2007. p. 1055–90.Hsu LY, Lee DG, Yeh SP, Bhurani D, Khanh BQ, Low CY, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: A prospective observational study. Clinical Microbiology and Infection. 2015 Jun 1;21(6):594.e7-594.e11.Fernández-Cruz A, Lewis RE, Kontoyiannis DP. How long do we need to treat an invasive mold disease in hematology patients? factors influencing duration of therapy and future questions. Clinical Infectious Diseases. 2020 Aug 1;71(3):685–92.Peter Donnelly J, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clinical Infectious Diseases. 2020 Sep 15;71(6):1367–76.Stohs E, Zimmer A. An Approach to Suspected Invasive Fungal Infection in Patients with Hematologic Malignancy and HCT Recipients with Persistent Neutropenic Fever Despite Mold-Active Prophylaxis. Vol. 14, Current Fungal Infection Reports. Springer; 2020. p. 89–98.Lien MY, Chou CH, Lin CC, Bai LY, Chiu CF, Yeh SP, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study. PLoS ONE. 2018 Jun 1;13(6).Nucci M, Anaissie E. How I Treat How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. 2014; 124(26):3858-69.Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Vol. 31, Blood Reviews. Churchill Livingstone; 2017. p. 17–29.Kubo H, Imataki O, Kubo YH, Uemura M, Kadowaki N. c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia. International Journal of Clinical Oncology. 2019 May 15;24(5):590–5.Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. Journal of Clinical Oncology. 2009 Aug 10;27(23):3849–54.Yılmaz G, Coşkun B, Elhan A, Azap A, Akan H. D-index: Febril nötropenik hastalarda ınvazif mantar enfeksiyonlarının tanımlanmasında yeni bir skorlama sistemi. Turkish Journal of Hematology. 2016;33(2):102–6.Instituto Nacional de Cancerología – ESE. Anuario estadístico 2017. Volumen 15.Bajpai VK, Khan I, Shukla S, Kumar P, Rather IA, Park YH, et al. Invasive Fungal Infections and Their Epidemiology: Measures in the Clinical Scenario. Vol. 24, Biotechnology and Bioprocess Engineering. Korean Society for Biotechnology and Bioengineering; 2019. p. 436–44.Ko BS, Chen WT, Kung HC, Wu UI, Tang JL, Yao M, et al. 2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. Vol. 51, Journal of Microbiology, Immunology and Infection. Elsevier Ltd; 2018. p. 287–301.Camplesi Junior M, Silva HM, Arantes AM, Costa CR, Ataides FS, Silva TC, et al. Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital. Revista da Sociedade Brasileira de Medicina Tropical. 2017;50(1):80–5.Lee SY, Yeo CL, Lee WH, Kwa AL, Koh LP, Hsu LY. Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in Singapore. BMC Research Notes. 2011;4.Vusirikala M, Supportive care in hematologic malignancies. Wintrobe’s Clinical Hematology. 2009;1747–90.Cooper B, Dubberke ER, Morris Engemann A, Freifeld AG, Greene JN, Ito JI, et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(7):882-913.Douglas AP, Slavin MA. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field. Expert Rev Anti Infect Ther. 2016;14(12):1165-1177.Nicolato A, Nouér SA, Garnica M, Portugal R, Maiolino A, Nucci M. Invasive fungal diseases in patients with acute lymphoid leukemia. Leukemia and Lymphoma. 2016;57(9):2084–9.Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control Journal of Antimicrobial Chemotherapy. 1998;41:95–105.Bodey GP, Buckley M, Sathe YS, Freireich EJ, Bethesda M. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328-40.Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345-51.Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005 Mar 15;103(6):1103-13.Abers MS, Ghebremichael MS, Timmons AK, Warren HS, Poznansky MC, Vyas JM. A Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis. Open Forum Infect Dis. 2016;3(1):ofw036.Natarajan SK, Narayan S, Liu Yin JA. Update on the Management of Febrile Neutropenia. European Oncology & Haematology, 2011;7(4):263-269Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013; 2013 (1): 423–427.Portugal RD, Garnica M, Nucci M. D-index and Prediction of Infection. Biol Blood Marrow Transplant 2010; 16: 1608.Garnica M, Sinhorelo A, Madeira L, Portugal R, Nucci M. Diagnostic-driven antifungal therapy in neutropenic patients using the D-index and serial serum galactomannan testing. Brazilian Journal of Infectious Diseases. 2016;20(4):354–9.Kanda Y, Kimura S-I, Iino M, Fukuda T, Sakaida E, Oyake T, et al. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol. 2020;38(8):815-822.Kimura S ichi, Kanda Y, Iino M, Fukuda T, Sakaida E, Oyake T, et al. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial. International Journal of Infectious Diseases. 2020;100:292–7.Kimura S ichi, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Yoshino N, et al. Impact of neutropenia evaluated in terms of the D-index on invasive fungal disease while on empiric or preemptive antifungal treatment strategy in the early phase after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2020 Dec;22(6):e13409.Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models Biometrika. 1986; 73(1):13–22Público generalORIGINAL1110470021.2022.pdf1110470021.2022.pdfTesis de Especialidad en Medicina Internaapplication/pdf1491882https://repositorio.unal.edu.co/bitstream/unal/80937/1/1110470021.2022.pdf697a63b4b56f8d96312a0361fa158639MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-84074https://repositorio.unal.edu.co/bitstream/unal/80937/2/license.txt8153f7789df02f0a4c9e079953658ab2MD52THUMBNAIL1110470021.2022.pdf.jpg1110470021.2022.pdf.jpgGenerated Thumbnailimage/jpeg5657https://repositorio.unal.edu.co/bitstream/unal/80937/3/1110470021.2022.pdf.jpg702d70cd1fd5f91827e431d7a1addfebMD53unal/80937oai:repositorio.unal.edu.co:unal/809372024-08-02 23:11:22.88Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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

D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá

Publicaciones similares